Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging.
We have developed biodegradable polymeric vesicles as a nanocarrier system for multimodal bio-imaging and anticancer drug delivery. The poly(lactic-co-glycolic acid) (PLGA) vesicles were fabricated by encapsulating inorganic imaging agents of superparamagnetic iron oxide nanoparticles (SPION), manganese-doped zinc sulfide (Mn:ZnS) quantum dots (QDs) and the anticancer drug busulfan into PLGA nanoparticles via an emulsion-evaporation method. T2∗-weighted magnetic resonance imaging (MRI) of PLGA-SPION-Mn:ZnS phantoms exhibited enhanced negative contrast with r2∗ relaxivity of approximately 523 s(-1) mM(-1) Fe. Murine macrophage (J774A) cellular uptake of PLGA vesicles started fluorescence imaging at 2 h and reached maximum intensity at 24 h incubation. The drug delivery ability of PLGA vesicles was demonstrated in vitro by release of busulfan. PLGA vesicle degradation was studied in vitro, showing that approximately 32% was degraded into lactic and glycolic acid over a period of 5 weeks. The biodistribution of PLGA vesicles was investigated in vivo by MRI in a rat model. Change of contrast in the liver could be visualized by MRI after 7 min and maximal signal loss detected after 4 h post-injection of PLGA vesicles. Histological studies showed that the presence of PLGA vesicles in organs was shifted from the lungs to the liver and spleen over time.
Division of Experimental Cancer Medicine, Department of Laboratory Medicine (LABMED), Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Fei
F
Ye
Division of Experimental Cancer Medicine, Department of Laboratory Medicine (LABMED), Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Asa
A
Barrefelt
Division of Experimental Cancer Medicine, Department of Laboratory Medicine (LABMED), Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Heba
H
Asem
Division of Experimental Cancer Medicine, Department of Laboratory Medicine (LABMED), Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Manuchehr
M
Abedi-Valugerdi
Division of Experimental Cancer Medicine, Department of Laboratory Medicine (LABMED), Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Ibrahim
I
El-Serafi
Division of Experimental Cancer Medicine, Department of Laboratory Medicine (LABMED), Karolinska Institutet, SE-141 86 Stockholm, Sweden.
Maryam
M
Saghafian
King Abdullah Institute for Nanotechnology, King Saud University, Riyadh 11451, P.O. Box 2455, Saudi Arabia. Electronic address: abusalah@ksu.edu.sa.
Khalid
K
Abu-Salah
King Abdullah Institute for Nanotechnology, King Saud University, Riyadh 11451, P.O. Box 2455, Saudi Arabia.
Salman
S
Alrokayan
Division of Functional Materials, School of Information and Communication Technology, Royal Institute of Technology (KTH), SE-164 40 Stockholm, Sweden.
Mamoun
M
Muhammed
Division of Experimental Cancer Medicine, Department of Laboratory Medicine (LABMED), Karolinska Institutet, SE-141 86 Stockholm, Sweden; Clinical Research Center, Karolinska University Hospital - Huddinge, SE-141 86 Stockholm, Sweden. Electronic address: moustapha.hassan@ki.se.
Moustapha
M
Hassan
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001672:Biocompatible Materials; D004337:Drug Carriers; D019344:Lactic Acid / Q000737:chemistry; D008279:Magnetic Resonance Imaging; D008280:Magnetics; D053768:Metal Nanoparticles; D051379:Mice; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D045663:Quantum Dots; D051381:Rats; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D001672:Biocompatible Materials; D004337:Drug Carriers; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid
Anticancer drug delivery; Biodegradable polymer; Busulfan; Fluorescence imaging; Magnetic resonance imaging; Multifunctional nanoparticles